1. Home
  2. REGN vs CI Comparison

REGN vs CI Comparison

Compare REGN & CI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

N/A

Current Price

$919.82

Market Cap

84.3B

Sector

Health Care

ML Signal

N/A

Logo The Cigna Group

CI

The Cigna Group

N/A

Current Price

$272.98

Market Cap

78.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
REGN
CI
Founded
1988
1792
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
84.3B
78.3B
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
REGN
CI
Price
$919.82
$272.98
Analyst Decision
Buy
Buy
Analyst Count
28
24
Target Price
★ $991.00
$344.40
AVG Volume (30 Days)
869.8K
★ 1.6M
Earning Date
10-30-2026
11-05-2026
Dividend Yield
0.41%
★ 2.29%
EPS Growth
8.19
★ 83.00
EPS
★ 37.37
18.02
Revenue
$5,872,227,000.00
★ $274,900,000,000.00
Revenue This Year
$31.18
$4.99
Revenue Next Year
$7.19
$3.82
P/E Ratio
$24.71
★ $15.15
Revenue Growth
★ 20.82
11.24
52 Week Low
$591.52
$257.85
52 Week High
$991.73
$318.05

Technical Indicators

Market Signals
Indicator
REGN
CI
Relative Strength Index (RSI) 57.41 34.66
Support Level $735.26 $267.62
Resistance Level $986.64 $274.69
Average True Range (ATR) 32.57 8.91
MACD -4.43 -3.60
Stochastic Oscillator 32.58 11.48

Price Performance

Historical Comparison
REGN
CI

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

About CI The Cigna Group

Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is with the Department of Defense, and it recently won a multiyear deal with top-tier insurer Centene. In health insurance and other benefits, Cigna primarily serves employers through self-funding arrangements, and the company operates mostly in the US with 16 million US and 2 million international medical members covered as of December 2025.

Share on Social Networks: